Clinical viewpoint

Self-collection, done right: the clinical case

Self-collection only improves outcomes if the sample is good, the pathway holds, and the data is clean. Here’s what “done right” actually requires.

Home / Resources / Insights

Self-collection has crossed from the fringe to the mainstream of American screening — and clinicians are right to ask the hard question: does it hold up to clinical scrutiny?

The evidence is increasingly reassuring. In May 2024 the FDA cleared self-collection for HPV screening, and in 2025 consensus guidelines from the ASCCP set out how self-collected specimens should be used in practice.[1][2] For colorectal screening, at-home FIT has been a mainstay of population programs for years. The direction of travel is clear: meet people where they are.

But "self-collection" is not one thing

A good self-collection program and a poor one can look identical on a slide and behave completely differently in the real world. The clinical quality of a result rests on things that happen long before the lab: whether the collection device is appropriate to the analyte, whether instructions are genuinely understood across languages and literacy levels, whether the sample is stabilized and transported within its window, and whether custody is unbroken and auditable.

The assay doesn't know whether the sample reached it in good condition. Everything upstream is where clinical quality is won or lost.

What "done right" requires

  • Fit-for-purpose devices — collection matched to the analyte and stabilized for real transit times.
  • Comprehension, not just instruction — multilingual, accessible guidance that reduces user error, delivered through +CURA.
  • Unbroken chain of custody — every sample timestamped and tracked, so an abnormal result is trusted and acted on.
  • Clean data into the record — results routed to the EHR with the right patient, the first time.

Self-collection widens access, and access is one of the biggest levers we have in cancer screening — particularly for people the system has historically missed. But access without quality is a false economy. Our job on the clinical side is to make sure that when we hand someone a kit, the result they eventually receive is one their clinician can rely on. That is the standard we hold the infrastructure to.

More insights

Keep reading

← All resources